Safety, Tolerability, and Pharmacokinetics of UHE-103 Cream in Subjects With Tinea Cruris and/or Tinea Pedis

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE1

Total Enrollment

42 participants

Study Classification

INTERVENTIONAL

Study Start Date

2022-02-17

Study Completion Date

2023-11-14

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This Phase 1 study has been designed to determine the safety, tolerability and pharmacokinetics (PK) of UHE 103 Cream compared to Naftin Cream, 2% under maximal use conditions for 2 weeks treatment in subjects with tinea cruris and/or tinea pedis

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

A Comparison Study of UHE-103 Cream in Subjects With Moccasin Type Tinea Pedis

NCT03897257

Tinea Pedis

COMPLETED PHASE2

Pharmacokinetic Study of Pediatric Subjects With Tinea Cruris and Tinea Pedis

NCT01712360

Tinea Pedis Tinea Cruris

COMPLETED PHASE4

Evaluate the Safety and Efficacy of Naftifine Hydrochloride Cream 2% and Naftin® Cream 2% in Patients With Tinea Pedis

NCT02132260

Tinea Pedis

COMPLETED PHASE1

Evaluate Safety and Efficacy of Naftifine Hydrochloride Gel 2% and Naftin® Gel 2% in Tinea Pedis

NCT02335255

Tinea Pedis

COMPLETED PHASE1

Evaluate the Safety & Bioequivalence of a Generic Butenafine Cream & Lotrimin Ultra® & Compare Both to a Vehicle Control in Treatment of Interdigital Tinea Pedis

NCT01580878

Tinea Pedis

COMPLETED PHASE1

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Tinea Cruris Tinea Pedis

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

UHE-103 Cream

Subjects will apply at least a total of 4 grams\* of the test article, covering both feet twice daily for 2 weeks

Group Type EXPERIMENTAL

UHE-103 Cream

Intervention Type DRUG

UHE-103 is an investigational combinational therapy containing keratolytic and antifungal

Naftin (naftifine hydrochloride) Cream, 2%

Subjects will apply at least a total of 5 grams\* of the test article, covering the interdigital areas of both feet and to the groin once daily for 2 weeks

Group Type ACTIVE_COMPARATOR

Naftin (naftifine hydrochloride) Cream

Intervention Type DRUG

Naftin (naftifine hydrochloride) Cream, 2%. Topical cream containing active drug

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

UHE-103 Cream

UHE-103 is an investigational combinational therapy containing keratolytic and antifungal

Intervention Type DRUG

Naftin (naftifine hydrochloride) Cream

Naftin (naftifine hydrochloride) Cream, 2%. Topical cream containing active drug

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Subject is a male or non-pregnant female 18 years of age or older.
2. Subject has provided written informed consent.
3. Subject has a clinical diagnosis of moccasin-type tinea pedis with at least moderate scaling on at least 1 foot at Visit 1/Screening;
4. Subject has a clinical diagnosis of interdigital tinea pedis with at least moderate scaling on at least 1 foot (without moccasin-type tinea pedis) and tinea cruris at Visit 1/Screening.
5. Subject is willing and able to apply the test article(s) as directed, comply with study instructions, and commit to all follow-up visits for the duration of the study.

Exclusion Criteria

1. Subject is pregnant, lactating, or is planning to become pregnant during the study.
2. Subject has any skin pathology or condition that could interfere with the evaluation of the test article or requires use of interfering topical, systemic, or surgical therapy.
3. Subject has any clinically significant medical abnormality or history of chronic disease (cardiovascular, gastrointestinal, neurological, hematopoietic, immunosuppression \[HIV\], hepatic \[Hepatitis B or C\], psychological, renal systems, or respiratory), including conditions (e.g., gastrointestinal surgery) that may interfere with the absorption, metabolism, or excretion of investigational product.
4. Subject has used any of the following topical products on the feet or groin within 4 weeks of Visit 2/Enrollment: antifungals, antibacterials, or corticosteroid therapy.
5. Subject has applied any topical naftifine products to any part of their body within 4 weeks of Visit 2/Enrollment.
6. Subject has used topical keratolytics (e.g., urea, ammonium lactate, salicylic acid) on the feet or groin within 1 week of Visit 2/Enrollment.
7. Subject has used any other topical products on the feet or groin within 24 hours of Visit 2/Enrollment including, but not limited to non-medicated moisturizers, antipruritics, analgesics, anesthetics, etc.
8. Subject has received systemic antifungal therapy within 8 weeks or 5 half lives of the antifungal (whichever is longer) of Visit 2/Enrollment.
9. Subject is currently enrolled in an investigational drug, biologic, or device study.
10. Subject has previously been enrolled in a study for UHE-103.
11. Subject has used an investigational drug, investigational biologic, or investigational device treatment within 30 days prior to Visit 2/Enrollment.
12. Subject has a history of sensitivity to any of the ingredients in the test articles.

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No